P1486: TRIALS IN PROGRESS: THE THRIVE STUDIES EVALUATING THE EFFICACY, SAFETY, AND LONG-TERM TREATMENT WITH INCLACUMAB, A P-SELECTIN INHIBITOR, IN PATIENTS WITH SICKLE CELL DISEASE
B. Andemariam,
A. Inati,
R. Colombatti,
C. Minniti,
C. Brown,
M. Hottmann,
S. Gray,
C. Hoppe,
M. Davis,
P. Yue
Affiliations
B. Andemariam
1 New England Sickle Cell Institute, University of Connecticut Health, Farmington, United States of America
A. Inati
2 Lebanese American University, Byblos and Beirut, Nini Hospital, Tripoli, Lebanon
R. Colombatti
3 Clinic of Pediatric Hematology Oncology, Department of Woman’s and Child’s Health, Azienda Ospedale – Università di Padova, Padua, Italy
C. Minniti
4 Albert Einstein College of Medicine, Bronx
C. Brown
5 Aflac Cancer and Blood Disorder Center of Children’s Healthcare of Atlanta and Department of Pediatrics, Emory School of Medicine, Atlanta
M. Hottmann
6 Global Blood Therapeutics, South San Francisco, United States of America
S. Gray
6 Global Blood Therapeutics, South San Francisco, United States of America
C. Hoppe
6 Global Blood Therapeutics, South San Francisco, United States of America
M. Davis
6 Global Blood Therapeutics, South San Francisco, United States of America
P. Yue
6 Global Blood Therapeutics, South San Francisco, United States of America
